Lakefront Biotherapeutics NV (GLPG)Healthcare | Biotechnology | Mechelen, Belgium |
USD
|
Hot Take ↕ | July 11, 2026, 10:29 a.m. UTC
The immediate outlook is neutral-to-slightly-bearish due to a confluence of deteriorating operational metrics and a lack of catalysts. While the stock recently rallied off its lows, the underlying business is showing clear signs of distress: revenue has collapsed by over 90% year-over-year, operating margins are deeply negative, and the company is cutting jobs and winding down cell therapy activities. The recent price action shows some resilience, trading above the 50-day moving average, but this appears to be a technical bounce rather than a reversal of the secular downtrend, especially given the weak statistical forecast confidence. There is no dividend income to offset these risks, making the investment purely speculative on a turnaround that has yet to materialize. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.023410 |
| AutoARIMA | 0.026172 |
| AutoETS | 0.026243 |
| MSTL | 0.026870 |
| MSTL_126 | 0.031727 |
| MSTL_48 | 0.041230 |
| MSTL_48_126 | 0.049387 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 3.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.628 |
| Excess Kurtosis | 0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.198 |
| Revenue per Share | 0.79185 |
| Market Cap | 1,862,327,296 |
| Trailing P/E | 3.18 |
| Forward P/E | -20.32 |
| Profit Margins | 46.83% |
| Website | https://www.glpg.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.009369373 |
| Address1 | Generaal De Wittelaan L11 A3 |
| All Time High | 274.03 |
| All Time Low | 4.7 |
| Ask | 35.21 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 177,230 |
| Average Volume | 154,819 |
| Average Volume10Days | 177,230 |
| Bid | 20.48 |
| Bid Size | 100 |
| Book Value | 2.8987663 |
| City | Mechelen |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Belgium |
| Currency | USD |
| Current Price | 27.73 |
| Current Ratio | 30.478 |
| Date Short Interest | 1,776,211,200 |
| Day High | 28.53 |
| Day Low | 27.16 |
| Debt To Equity | 0.198 |
| Ebitda | 662,956,480 |
| Ebitda Margins | 0.63517 |
| Enterprise To Ebitda | -1.648 |
| Enterprise To Revenue | -1.047 |
| Enterprise Value | -1,092,503,680 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fax | 32 1 534 29 01 |
| Fifty Day Average | 29.6654 |
| Fifty Two Week High | 37.78 |
| Fifty Two Week Low | 26.62 |
| Financial Currency | EUR |
| First Trade Date Epoch Utc | 1,229,610,600 |
| Float Shares | 44,522,059 |
| Forward Eps | -1.0439789 |
| Forward P E | -20.315018 |
| Free Cashflow | 210,970,496 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.5399 |
| Gross Profits | 563,524,992 |
| Held Percent Insiders | 0.25354 |
| Held Percent Institutions | 0.22308001 |
| Implied Shares Outstanding | 67,159,294 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. |
| Long Name | Lakefront Biotherapeutics NV |
| Market Cap | 1,862,327,296 |
| Max Age | 86,400 |
| Message Board Id | finmb_1716658 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 487,931,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,001,898,200 |
| Number Of Analyst Opinions | 1 |
| Open | 28.53 |
| Operating Cashflow | -301,599,008 |
| Operating Margins | -9.82919 |
| Payout Ratio | 0.0 |
| Phone | 32 1 534 29 00 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 9.566138 |
| Price To Sales Trailing12 Months | 1.7842623 |
| Profit Margins | 0.46828997 |
| Quick Ratio | 30.235 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 28.53 |
| Regular Market Day Low | 27.16 |
| Regular Market Open | 28.53 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 286,745 |
| Return On Assets | 0.10655 |
| Return On Equity | 0.16261 |
| Revenue Growth | -0.914 |
| Revenue Per Share | 0.79185 |
| Sand P52 Week Change | 0.19142711 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 65,897,071 |
| Shares Percent Shares Out | 0.0208 |
| Shares Short | 1,371,531 |
| Shares Short Previous Month Date | 1,773,360,000 |
| Shares Short Prior Month | 910,692 |
| Short Name | Galapagos NV |
| Short Percent Of Float | 0.0339 |
| Short Ratio | 6.95 |
| Symbol | GLPG |
| Target High Price | 27.262846 |
| Target Low Price | 27.262846 |
| Target Mean Price | 27.262846 |
| Target Median Price | 27.262846 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 2,982,240,000 |
| Total Cash Per Share | 45.273 |
| Total Debt | 6,435,000 |
| Total Revenue | 1,043,752,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | 8.71 |
| Trailing P E | 3.1836967 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 32.00045 |
| Underlying Symbol | GLPG |
| Uuid | 8ade642a-64d7-348a-ab37-8edc49ae1242 |
| Volume | 286,745 |
| Website | https://www.glpg.com |
| Zip | 2,800 |